BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 21816200)

  • 21. Gene gun administration of therapeutic HPV DNA vaccination restores the efficacy of prolonged defrosted viral based vaccine.
    Lin CT; Yen CF; Shaw SW; Yen TC; Chen YJ; Soong YK; Lai CH
    Vaccine; 2009 Dec; 27(52):7352-8. PubMed ID: 19781679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
    Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
    Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model.
    Cerutti ML; Alonso LG; Tatti S; de Prat-Gay G
    Int J Cancer; 2012 Apr; 130(8):1813-20. PubMed ID: 21780110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers.
    Radaelli A; De Giuli Morghen C; Zanotto C; Pacchioni S; Bissa M; Franconi R; Massa S; Paolini F; Muller A; Venuti A
    Virus Res; 2012 Dec; 170(1-2):44-52. PubMed ID: 22951311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression.
    Marquez JP; Rivera R; Kang KH; Gardner MB; Torres JV
    Viral Immunol; 2012 Apr; 25(2):141-52. PubMed ID: 22486305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
    Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
    Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
    Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
    Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
    Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human papillomavirus vaccines.
    Breitburd F; Coursaget P
    Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
    Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
    Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
    Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
    J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancement of Ad-CRT/E7-mediated antitumor effect by preimmunization with L. lactis expressing HPV-16 E7.
    Rangel-Colmenero BR; Gomez-Gutierrez JG; Villatoro-Hernández J; Zavala-Flores LM; Quistián-Martínez D; Rojas-Martínez A; Arce-Mendoza AY; Guzmán-López S; Montes-de-Oca-Luna R; Saucedo-Cárdenas O
    Viral Immunol; 2014 Nov; 27(9):463-7. PubMed ID: 25216057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
    Bolhassani A; Zahedifard F; Taghikhani M; Rafati S
    Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
    Granadillo M; Vallespi MG; Batte A; Mendoza O; Soria Y; Lugo VM; Torrens I
    Vaccine; 2011 Jan; 29(5):920-30. PubMed ID: 21145912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
    Bae SH; Park YJ; Park JB; Choi YS; Kim MS; Sin JI
    Clin Cancer Res; 2007 Jan; 13(1):341-9. PubMed ID: 17200373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.